Ultragenyx Pharmaceutical Inc. (RARE) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Crysvita Total Revenue | 145M | FY2025-Q4 |
| Dojolvi Revenue | 32M | FY2025-Q4 |
| Evkeeza Revenue | 17M | FY2025-Q4 |
| Mepsevi Revenue | 13M | FY2025-Q4 |
| Crysvita Product Sales (Latin America and Turkey) | 40M | FY2025-Q4 |
| Crysvita Royalty Revenue in Europe | 8M | FY2025-Q4 |
| Crysvita Royalty Revenue in the United States and Canada | 97M | FY2025-Q4 |
| Non-Cash Stock-Based Compensation Included in Operating Expenses | 37M | FY2025-Q3 |
| CRISVITA Revenue in Latin America and Türkiye | 47M | FY2025-Q3 |
| Crysvita Revenue in the United States and Canada | 57.19M | FY2025-Q3 |
Back to RARE overview · RARE earnings · RARE holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.